Insider trade

CEO sold ~$19K of UTHR shares in the open market

Traded Sep 24, 2026 · Filed Sep 26, 2026

~$19K
Approx. value · 40 sh @ $480.33: 324K
Holds after · shares reported: +14.7%
stock since the trade · S&P 500 +1.6%, $472.21 → $541.62 on Oct 6

Why it stands out

The CEO of United Therapeutics sold $19K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 24, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 26, 2026

CEOIndirect holding<$25KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$19,213

Shares × reported transaction price

Timing vs results

50 days after results of Aug 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $472.21 on Sep 24, 2026, 14% above its 52-week low and 21% below its high, after an 8% drop over the previous 30 trading days

52-week range $415.34 (Oct 28, 2025) to $596.76 (May 6, 2026), 31% of the way up, from 244 adjusted closes. 30 trading days earlier: $511.72 on Aug 12, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001106578-26-000149
Filed / recorded: Sep 26, 2026, 12:31 AM UTC
Added to OQRO: Oct 6, 2026, 9:34 PM UTC
Parser: form4-xml-v2
Data quality: Verified: identifiers matched exactly
Issuer: UNITED THERAPEUTICS Corp
Issuer CIK: 1082554
Ticker: UTHR
Reporting person: Martine A Rothblatt
Relationship: Director, Officer
Officer title: Chairperson & CEO
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Sep 24, 2026
Transaction code: S
Shares / units: 40
Price per share: $480.33
Acquired / disposed: Disposed (D)
Shares owned after: 324,443
Ownership form: Indirect — by Trust
Amendment: No

Footnotes from the filing

This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

Around the same time

Martine A RothblattChairperson & CEO

Filed yesterday

9,500Shares · @ $117.76

Traded Oct 5 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

More Official record

Martine A Rothblatt (Chairperson & CEO) sold ~$269K of United Therapeutics

Scheduled in advanceFiled yesterday

Martine A Rothblatt (Chairperson & CEO) sold ~$486K of United Therapeutics

Scheduled in advanceFiled yesterday